Trimipramine

Trimipramine
Systematic (IUPAC) name
(±)-3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine
Clinical data
Trade names Surmontil
AHFS/Drugs.com monograph
MedlinePlus a602010
License data
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration		 Oral, IM, IV
Legal status
Legal status
Pharmacokinetic data
Bioavailability 41%[1][2][3][4]
Protein binding 94.9%[1][2][3][4]
Metabolism Hepatic[1][2][3][4]
Biological half-life 23-24 hours[1][2][3][4]
Excretion Renal[1][2][3][4]
Identifiers
CAS Number 739-71-9 YesY
ATC code N06AA10 (WHO)
PubChem CID 5584
IUPHAR/BPS 7317
DrugBank DB00726 YesY
ChemSpider 5382 YesY
UNII 6S082C9NDT YesY
KEGG D00394 YesY
ChEBI CHEBI:9738 YesY
ChEMBL CHEMBL644 YesY
Chemical data
Formula C20H26N2
Molar mass 294.434 g/mol
  (verify)

Trimipramine (Surmontil, Rhotrimine, Stangyl) is a tricyclic antidepressant (TCA) with antipsychotic and sedative properties.

Medical uses

Trimipramine's primary use in medicine is in the treatment of major depressive disorder,[5][6] especially where sedation is required due to its prominent sedative effects.[6] Trimipramine also has some weak antipsychotic effects which are less pronounced than with the phenothiazine antipsychotic perazine.[7][8][9]

Trimipramine is the only effective drug against insomnia known so far that does not alter the normal sleep architecture (there is evidence in medical journals that refute this last statement). In particular, it does not suppress REM sleep, and dreams are said to brighten during treatment.[10]

Adverse effects

Common adverse effects include:[1][2][3][4][5][6]

Note: Bolded adverse effects are serious ones.

  • Sedation — especially common with trimipramine compared to the other TCAs
  • Anticholinergic effects including:
- dry mouth
- blurred vision
- mydriasis
- decreased lacrimation
- constipation
- urinary hesitancy or retention
- reduced GI motility
- tachycardia (high heart rate)
- anticholinergic delirium (particularly in the elderly and in Parkinson's disease)
  • Weight gain
  • Orthostatic hypotension
  • Sexual dysfunction including impotence, loss of libido and other sexual adverse effects
  • Tremor
  • Dizziness
  • Sweating
  • Anxiety
  • Insomnia
  • Agitation
  • Rash

whereas adverse effects with an unknown incidence includes:[1][2][3][4][5][6]

and rare adverse effects include:[1][2][3][4][5][6]

- Agranulocytosis
- Thrombocytopenia
- Eosinophilia
- Leukopaenia

Contraindications

Contraindications include:[1][2][3][4][5][6]

Interactions

Trimipramine should not be given with sympathomimetic agents such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine.

Barbiturates may increase the rate of metabolism. Trimipramine should be administered with care in patients receiving therapy for hyperthyrodism.[1][2][3][4][5][6]

Overdose

Compared to other tricyclic antidepressants trimipramine is relatively safe in overdose, although it is more dangerous than the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) but less dangerous than bupropion in cases of overdose.[11]

Mechanism of action

Trimipramine's mechanism of action differs from other TCAs. It is a weak to moderate[12] reuptake inhibitor of serotonin, and an extremely weak inhibitor of norepinephrine and dopamine reuptake. Its main effects are due to considerable receptor antagonism as follows:[9][12][13]

Transporter/Receptor Ki (nM)[9][12][13] Species
SERT 149 Human
NET 2450 Human
DAT 3780 Human
H1 1.4 Human
α1 24 Rat
α2A 1380 Rat
α2B 380 Rat
mAChRs 59 Human
5-HT2A 19.5 Rat
5-HT2C 537 Rat
5-HT3 9120 Rat
D1 347 Rat
D2 57.5 Rat

Pharmacokinetics

Trimipramine is a racemic compound with two enantiomers. CYP2C19 is responsible for the demethylation of (D)- and (L)-trimipramine to (D)- (L)-desmethyltrimipramine, respectively, and CYP2D6 is responsible for the 2-hydroxylation of (D)- and (L)-desmethyltrimipramine to (D)- and (L)-2-hydroxydesmethyltrimipramine, respectively.[14] CYP2D6 also metabolizes (L)-trimipramine into (L)-2-hydroxytrimipramine.[14]

History

Trimipramine maleate (as Surmontil) oral capsules were first approved by the Food and Drug Administration prior to January 1, 1982 in 25 mg and 50 mg formulations, with the 100 mg formulation having been approved on September 15, 1982. A generic version of all three formulations was given FDA approval on August 2, 2006.[15]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 "PRODUCT INFORMATION SURMONTIL® Tablets and Capsules" (PDF). TGA eBusiness Services. Aspen Pharmacare Australia Pty Ltd. 28 November 2012. Retrieved 30 November 2013.
  2. 1 2 3 4 5 6 7 8 9 10 "SURMONTIL (trimipramine maleate) capsule [Duramed Pharmaceuticals Inc]". DailyMed. Duramed Pharmaceuticals Inc. December 2012. Retrieved 30 November 2013.
  3. 1 2 3 4 5 6 7 8 9 10 "Surmontil, Trimip (trimipramine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 30 November 2013.
  4. 1 2 3 4 5 6 7 8 9 10 "Trimipramine 50mg Capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Zentiva. 19 November 2012. Retrieved 30 November 2013.
  5. 1 2 3 4 5 6 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  6. 1 2 3 4 5 6 7 Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
  7. ↑ Bender, S; Olbrich, HM; Fischer, W; Hornstein, C; Schoene, W; Falkai, P; Haarmann, C; Berger, M; Gastpar, M (March–April 2003). "Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine". Pharmacopsychiatry 36 (2): 61–69. doi:10.1055/s-2003-39043. PMID 12734763.
  8. ↑ Eikmeier, G; Berger, M; Lodemann, E; Muszynski, K; Kaumeier, S; Gastpar, M (Winter 1991). "Trimipramine: An atypical neuroleptic?". International Clinical Psychopharmacology 6 (3): 147–153. doi:10.1097/00004850-199100630-00003. PMID 1806621.
  9. 1 2 3 Gross, G; Xin, X; Gastpar, M (November 1991). "Trimipramine: Pharmacological reevaluation and comparison with clozapine". Neuropharmacology 30 (11): 1159–1166. doi:10.1016/0028-3908(91)90160-D. PMID 1663593.
  10. ↑ Schredl, M; Berger, M; Riemann, D (May 2009). "The effect of trimipramine on dream recall and dream emotions in depressive outpatients". Psychiatry Research 167 (3): 279–286. doi:10.1016/j.psychres.2008.03.002. PMID 19403177.
  11. ↑ White, N; Litovitz, T; Clancy, C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type" (PDF). Journal of Medical Toxicology 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
  12. 1 2 3 Roth, BL; Driscol, J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 30 November 2013.
  13. 1 2 Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
  14. 1 2 Eap CB, Bender S, Gastpar M, et al. (2000). "Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients". Ther Drug Monit 22 (2): 209–14. doi:10.1097/00007691-200004000-00012. PMID 10774635.
  15. ↑ "Generic Surmontil Availability". Drugs.com. Retrieved 22 March 2013.
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.